Review for "A systematic review of the impact of chronic pain on adolescents’ school functioning and school personnel responses to managing pain in the schools"

School plays a central role in young people’s lives, offering a developmental environment that fosters crucial academic, emotional, cognitive, and social milestones. This chapter presents a critical discussion of how a young person’s school functioning can be negatively affected by chronic pain. We highlight how the impact of chronic pain, and associated psychosocial factors, goes beyond school absenteeism to influence school engagement, executive functioning skills, and social skills development. Furthermore, the challenges teachers face to provide an inclusive school environment for young people with chronic pain will be discussed in depth. The chapter ends with suggestions of how to overcome the barriers to implementing a comprehensive approach towards school functioning within both research and clinical practice, including reviewing standardized tools to assess school impairment and offering guidance for biopsychosocially informed approaches to foster adaptive school functioning in young people with chronic pain.

The School Experiences of Siblings of Children With Chronic Illness: Australian Parents’ Perceptions

The Educational and Developmental Psychologist ◽

10.1017/edp.2018.3 ◽

2018 ◽

Vol 35 (1) ◽

pp. 36-50 ◽

Cited By ~ 1

Author(s):

Lucy L. Gan ◽

Alistair Lum ◽

Claire E. Wakefield ◽

Barbara M. Donnan ◽

Glenn M. Marshall ◽

...

Keyword(s):

Chronic Illness ◽

School Personnel ◽

School Experiences ◽

Psychological Support ◽

School Functioning ◽

Sibling Support ◽

Telephone Interviews ◽

School Based ◽

The Impact ◽

Consistent Support

Children with chronic illness often experience difficulties at school, yet little is known about the impact of the child's illness on siblings’ school experiences. This study investigated parents’ perceptions of siblings’ school experiences and school support. We conducted semi-structured telephone interviews with 27 parents of children with a chronic illness who had a sibling or siblings (4–25 years), representing the experiences of 31 siblings. Interviews were audio-recorded, transcribed, and analysed using content analysis. Parents believed that 14 of 31 (45.2%) siblings had school difficulties related to the ill child, such as increased anxiety or stress at school, lack of attention from teachers, and changes in behaviour as a result of increased carer responsibilities. Parents identified increased absenteeism due to the ill child's hospitalisation and the impact of parent absences on sibling school functioning. Parents described general and psychological support from the school, and the importance of monitoring the sibling at school and focusing on their unique needs. Overall, our findings suggest the need for a school-based sibling support model that combines psycho-education for siblings and school personnel, individualised sibling psychological support, and shared school and parent responsibility in normalising the sibling experience and providing consistent support.

P138 Impact of chronic pain on adolescents’ school functioning: a systematic review

10.1136/archdischild-2019-epa.493 ◽

2019 ◽

Author(s):

Fatimah Alsaggaf ◽

Imelda Coyne

Keyword(s):

Systematic Review ◽

Chronic Pain ◽

School Functioning

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: May 2021 Update

10.23970/ahrqepccerplantpain3 ◽

2021 ◽

Author(s):

Marian S. McDonagh ◽

Jesse Wagner ◽

Azrah Y. Ahmed ◽

Benjamin Morasco ◽

Devan Kansagara ◽

...

Keyword(s):

Systematic Review ◽

Chronic Pain ◽

Adverse Events ◽

Progress Report ◽

Pain Severity ◽

Short Term Treatment ◽

Serious Adverse Events ◽

Whole Plant ◽

Increased Risk ◽

The Impact

Overview This is the third quarterly progress report for an ongoing living systematic review on cannabis and other plant-based treatments for chronic pain. The first progress report was published in January 2021 and the second in March 2021. The draft systematic review was available for public comment from May 19 through June 15, 2021, on the Agency for Healthcare Research and Quality (AHRQ) Effective Health Care website. The systematic review synthesizes evidence on the benefits and harms of plant-based compounds (PBCs), such as cannabinoids and kratom, used to treat chronic pain, addressing concerns about severe adverse effects, abuse, misuse, dependence, and addiction. The purpose of this progress report is to describe the cumulative literature identified thus far. This report will be periodically updated with new studies as they are published and identified, culminating in an annual systematic review that provides a synthesis of the accumulated evidence. Main Points In patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to <6 months): • Studies of cannabis-related products were grouped based on their tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio using the following categories: high THC to CBD, comparable THC to CBD, and low THC to CBD. • Comparable THC to CBD ratio oral spray is probably associated with small improvements in pain severity and may be associated with small improvements in function. There was no effect in pain interference or serious adverse events. There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea. • Synthetic THC (high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation, and large increased risk of nausea. Synthetic THC is probably associated with a large increased risk of dizziness. • Extracted whole-plant high THC to CBD ratio products may be associated with large increases in risk of withdrawal due to adverse events and dizziness. • Evidence on whole-plant cannabis, low THC to CBD ratio products (topical CBD), other cannabinoids (cannabidivarin), and comparisons with other active interventions was insufficient to draw conclusions. • Other key adverse event outcomes (psychosis, cannabis use disorder, cognitive deficits) and outcomes on the impact on opioid use were not reported. • No evidence on other plant-based compounds, such as kratom, met criteria for this review.